 |
30 Diseases |  |
2 Trials |
|
2 Trials |  |
15 News |  |
- DZD8586 / Dizal Pharma
First Report of Phase 1 Studies of DZD8586, a BBB Penetrant LYN/BTK Dual Inhibitor, in Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL) (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_5907;
P1, P1/2
Introduction Resistance to covalent (ibrutinib, acalabrutinib and zanubrutinib) and non-covalent BTK inhibitors (pirtobrutinib) is an emerging clinical challenge...Methods TAI-SHAN1 (NCT05844956; CTR20220558) and TAI-SHAN5 (NCT05824585) are phase 1 dose escalation and expansion studies in patients with r/r B-NHL...The combination of BBB penetration, dual inhibition of LYN/BTK and potential to overcome C481S mutant CLL and other covalent BTKi resistant lymphomas suggest this may be a useful agent. Updated data will be presented at the meeting.
- |||||||||| SHAN6 (DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)) / Sanofi, Shan5 (DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine) / Sanofi
New P3 trial: Study of Full Schedule (3-Dose of Shan6 (EUDRACT) - Jan 26, 2023
P3, N=690, , Sponsor: Sanofi Pasteur
- || Shan5 (DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine) / Sanofi
This made my day. @AnnieGunther5 @web3filmsonly @tortoricitheo @ericvautier @BlaecBejarano @TheFantasyHorn @wevatec @max60708275 @GlopesMd @pawankumaar667 @chrishan517 @phantazonia @scratchboom @man_shadowages (Twitter) - Nov 13, 2022
- ||||||| SHAN6 (DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)) / Sanofi
Trial completion: Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - May 9, 2022
P3, N=460, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Updated data will be presented at the meeting. Active, not recruiting --> Completed
- |||||||||| SHAN6 (DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)) / Sanofi
New P3 trial: Study of DTwP-HepB-Hib-IPV (SHAN6™) vaccine administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in Thailand (EUDRACT) - Feb 19, 2022
P3, N=460, , Sponsor: Sanofi Pasteur
- ||||| SHAN6 (DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)) / Sanofi
Enrollment closed: Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - Mar 29, 2021
P3, N=460, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| SHAN6 (DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)) / Sanofi
Trial completion date, Trial primary completion date: Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - Feb 17, 2021
P3, N=460, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Active, not recruiting Trial completion date: Mar 2022 --> Dec 2021 | Trial primary completion date: Nov 2020 --> Feb 2021
- ||| Shan5 (DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine) / Sanofi
#GoodMorningTwitterWorld @ishita_002 @BuchHitakshi @bhogleharsha @sejalbhagat54 @AmbaniKishan5 @v_limbachiya @DrSapnaPatel @niilshihori @RupalAhir2 @kt_27070 @jappsh @hiralsalu @binal_71912 @_sally_17_06 @SeemaSh46712468 @pateldpl3 @goodmorning_biz (Twitter) - Nov 30, 2020
- ||| Shan5 (DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine) / Sanofi
#GoodMorningTwitterWorld @ishita_002 @BuchHitakshi @bhogleharsha @AmbaniKishan5 @sejalbhagat54 @DrSapnaPatel @RupalAhir2 @kt_27070 @jappsh @hiralsalu @binal_71912 @_sally_17_06 @SeemaSh46712468 #MorningThoughts (Twitter) - Nov 29, 2020
- || Shan5 (DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine) / Sanofi
I am looking for a super simple paper on adverse selection that I can assign to my undergraduates--anyone have a suggestion? @Shooshan5 @atheendar @EGolberstein @A_Schwa @asacarny (Twitter) - Oct 15, 2020
- |||||| SHAN6 (DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)) / Sanofi
Enrollment open: Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - Jul 20, 2020
P3, N=460, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial completion date: Mar 2022 --> Dec 2021 | Trial primary completion date: Nov 2020 --> Feb 2021 Not yet recruiting --> Recruiting
- |||||||||| SHAN6 (DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)) / Sanofi
New P3 trial: Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - Jun 12, 2020
P3, N=460, Not yet recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- || Shan5 (DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine) / Sanofi, Shan TT (tetanus toxoid vaccine) / Generic mfg.
Does anyone have plans to do an online health policy seminar? @VUHealthPol @EGolberstein @IncidentalEcon @KosaliSimon @DavidSlusky @Shooshan5 @LaurawherryR @smilleralert @Prof_HeidiAllen @asacarny + so many other people... (Twitter) - Mar 26, 2020
- || Shan5 (DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine) / Sanofi, Shan TT (tetanus toxoid vaccine) / Generic Mfg.
@Shooshan5 (Twitter) - Nov 19, 2019
- ||| Shan5 (DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine) / Sanofi, Shan TT (tetanus toxoid vaccine) / Generic Mfg.
Clinical: if you are studying hospitals and want to know about potential data sources, check out this great summary from @Shooshan5 and many more folks! (Twitter) - Nov 14, 2019
- || Shan5 (DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine) / Sanofi, Shan TT (tetanus toxoid vaccine) / Generic Mfg.
3 fun facts / 5 scientists 1. I'm Bashkir (small ethnicity in the middle of Russia) 2. I met my husband in a night club (how often does that end in a 10+ year relationship!) 3. I've lived on 4 continents (so far!) @ashtroid22 @karenerrichetti @DianeViji @Shooshan5 @SexDrugsPD (Twitter) - Aug 18, 2019
- ||| Shan5 (DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine) / Sanofi, Shan TT / Shantha Biotechnics
Head-to-Head: That's why we need to continue the ACCESS trial even though the study shows non-inferiority. Maybe we will see the same results, but then again, maybe not. Either way, it might speak towards differences between economic models of acute CV care. @shooshan5 https://t.co/VcIYVbntpZ (Twitter) - Apr 1, 2019